Gujarat Kidney and Super Speciality
141.25
-2.02(-1.41%)
Market Cap₹1,113.66 Cr
PE Ratio84.59
Company Performance:
1D-1.41%
1M+27.94%
6M+35.12%
1Y+35.12%
5Y+35.12%
View Company Insightsright
More news about Gujarat Kidney and Super Speciality
26Mar 26
Gujarat Kidney Completes Postal Ballot Notice Dispatch for IPO Fund Reallocation
Gujarat Kidney and Super Speciality Limited has completed the dispatch of its postal ballot notice to shareholders, announcing through newspaper publications on March 26, 2026. The company seeks approval for reallocating ₹3,692.50 lakhs of unutilized IPO funds from women's hospital and robotics equipment to developing a multi-specialty hospital in Bharuch and dialysis services collaboration. The e-voting process runs from March 27 to April 25, 2026, with results expected within two working days.
 no imag found
23Mar 26
Gujarat Kidney and Super Speciality Limited Acquires Parekhs Hospital for ₹77 Crore
Gujarat Kidney and Super Speciality Limited completed acquisition of Parekhs Hospital Private Limited as wholly owned subsidiary on March 22, 2026, for ₹77 crore cash consideration. The target company, incorporated in 2006, operates in medical and healthcare services with revenues of ₹25.67 crore in FY25. The strategic acquisition aims to strengthen presence in healthcare sector and diversify business portfolio.
 no imag found
21Mar 26
Gujarat Kidney Pays ₹6.61 Lakh Penalty to NSE and BSE for Regulatory Non-Compliance
Gujarat Kidney and Super Speciality Limited has completed payment of regulatory penalties totaling ₹6,60,800 to NSE and BSE for failing to submit quarterly financial results within prescribed timelines. The company paid ₹3,30,400 to each exchange via RTGS on March 20, 2026, following penalty notices received on March 17, 2026, and has formally communicated the settlement to both exchanges.
 no imag found
19Mar 26
Gujarat Kidney Appoints Auditors and Approves Postal Ballot with Q2 FY25 Results
Gujarat Kidney And Superspeciality Limited conducted a board meeting on March 19, 2026, appointing Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26. The board also approved postal ballot notice and ratified Q2 FY25 financial results, which showed consolidated revenue growth of 37.40% to ₹1,292.88 lacs despite a decline in net profit.
 no imag found
13Mar 26
Gujarat Kidney And Super Speciality Limited Reports Mixed Q2FY26 Results with Revenue Decline
Gujarat Kidney And Super Speciality Limited reported Q2FY26 standalone revenue of ₹964.26 lacs, up 2.47% YoY, but net profit declined 22.17% to ₹230.12 lacs due to rising expenses. Half-year performance showed stronger growth with revenue increasing 12.97% to ₹2,109.25 lacs and net profit rising 10.12% to ₹620.10 lacs. Consolidated results demonstrated significant revenue growth of 37.40% to ₹1,292.88 lacs, reflecting successful expansion through subsidiaries, though profitability remained under pressure with EPS declining across both standalone and consolidated operations.
 no imag found
1 Year Returns:+35.12%
Industry Peers
Apollo Hospitals
8,404.00
(+0.50%)
Max Healthcare Institute
1,000.85
(-2.19%)
Fortis Healthcare
970.35
(+1.04%)
Narayana Hrudayalaya
1,940.00
(+4.55%)
Aster DM Healthcare
746.90
(-1.28%)
Global Health
1,249.30
(+0.90%)
Park Medi World
279.09
(+7.68%)